Compare Abeona Therapeutics Inc (ABEO) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Keysight Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Keysight Technologies Inc trades at $315.27 (market cap $52.83B). The key difference: Keysight Technologies Inc is far larger — about 141.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Keysight Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | KEYS | |
|---|---|---|
Market Cap | $373.32M | $52.83B |
Sector | Health | Technology |
52-Week High | $7.23 | $373.34 |
52-Week Low | $4.17 | $158.51 |
Enterprise Value | $228.22M | $53.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Keysight Technologies (KEYS) trades at $309.12, down 1.51% today, with a bearish technical signal despite strong earnings beats in recent quarters. The company maintains solid profitability with a 63.67% gross margin and 17.31% net margin, though valuation multiples like a P/E of 51.49 appear elevated. Recent news highlights strategic collaborations in 6G and photonics, positioning KEYS for growth in AI and wireless markets.
The outlook is mixed: analyst consensus is bullish with a $390.30 price target (75% buy ratings), but technical weakness and high valuation pose near-term risks. Upside hinges on execution in high-frequency RF and photonics markets, while downside risks include competitive pressures and integration challenges from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
